ReviewAdvances in cancer research2015
Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.
Review in Advances in cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.Frontiers in immunology · 2022Pooled it
- Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine.PLoS pathogens · 2022Trial
- Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.Cancer immunology, immunotherapy : CII · 2021Trial
- Oral exposure to PET microplastics induces the pancreatic immune response and oxidative stress in immature pigs.BMC genomics · 2025Article
- Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection.Journal of surgical oncology · 2025Article
- Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma.Nature communications · 2024Article
- Exploring the prognostic implications of cuproptosis-associated alterations in clear cell renal cell carcinoma via in vitro experiments.Scientific reports · 2024Article
- A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.Clinical and experimental medicine · 2023Article
- New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review).Experimental and therapeutic medicine · 2023Review
- B Cells in Breast Cancer Pathology.Cancers · 2023Review
- Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer.Cancer immunology, immunotherapy : CII · 2022Article
- Tertiary lymphoid structure and decreased CD8iScience · 2022Article
- Article
- Lymphotoxins Serve as a Novel Orchestrator in T1D Pathogenesis.Frontiers in immunology · 2022Review
- Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses.Frontiers in cell and developmental biology · 2022Review
- Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy.Oncology letters · 2021Review
- Review
- STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.Frontiers in immunology · 2021Review
- Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.Frontiers in immunology · 2021Review
- The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The inflammatory status of the tumor microenvironment (TME) has been heavily investigated in recent years. Chemokine- and cytokine-signaling pathways such as CCR7, CXCR5, lymphotoxin, and IL-36, which are involved in the generation of secondary lymphoid organs and effector immune responses, are now recognized as having value both as prognostic factors and as immunomodulatory therapeutics in the context of cancer. Furthermore, when produced in the TME, these mediators have been shown to promote the recruitment of immune cells, including T cells, B cells, dendritic cells (DCs), and other specialized immune cell subsets such as follicular DCs and T follicular helper cells, in association with the formation of "tertiary" lymphoid structures (TLSs) within or adjacent to sites of disease. Although TLSs are composed of a heterogeneous collection of immune cell types, whose composition differs based on cancer subtype, the qualitative presence of TLSs has been shown to represent a biomarker of good prognosis for cancer patients. A comprehensive understanding of the role each of these pathways plays within the TME may support the rational design of future immunotherapies to selectively promote/bolster TLS formation and function, leading to improved clinical outcomes across the vast range of solid cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.